U.S. markets closed
  • S&P Futures

    -3.00 (-0.07%)
  • Dow Futures

    -19.00 (-0.06%)
  • Nasdaq Futures

    +4.00 (+0.03%)
  • Russell 2000 Futures

    +1.90 (+0.09%)
  • Crude Oil

    +0.32 (+0.45%)
  • Gold

    +0.10 (+0.01%)
  • Silver

    -0.00 (-0.02%)

    +0.0008 (+0.07%)
  • 10-Yr Bond

    -0.0610 (-4.04%)
  • Vix

    +2.95 (+16.62%)

    +0.0010 (+0.08%)

    +0.0580 (+0.05%)

    -22.82 (-0.06%)
  • CMC Crypto 200

    -51.42 (-5.47%)
  • FTSE 100

    -135.96 (-1.90%)
  • Nikkei 225

    -54.22 (-0.19%)

Top Research Reports for Novo Nordisk, IBM, & Deere

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·6 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Thursday, May 20, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk AS (NVO), International Business Machines Corporation (IBM), and Deere & Company (DE). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry in the last one-year period (+23.4% vs. +11.8%). In fact, Novo Nordisk’s earnings and revenues beat estimates in Q1. What’s more, Ozempic is off to a solid start and the launch of Rybelsus also looks impressive, per the Zacks analyst.

Victoza, Ozempic, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of existing drugs will further boost sales. In 2021, the company will continue its focus on commercial execution while conducting more late-stage clinical studies than ever to meet the needs of the people living with diabetes and other serious chronic diseases.

However, lower realized prices in the Unites States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will affect sales. Sales are also being negatively impacted by COVID-19-related stocking, which remains a woe.

(You can read the full research report on Novo Nordisk here >>>)

Shares of IBM have outperformed the Zacks Computer - Integrated Systems industry in the year-to-date period (+13.8% vs. +12.4%). The Zacks analyst believes that IBM is well-poised to benefit from solid uptake of the company’s cloud-based solutions. Synergies from Red Hat buyout are strengthening its competitive position in the hybrid cloud market.

The company is also likely to gain from spin-off of legacy infrastructure services business as it focuses on its hybrid cloud strategy. Strong patent portfolio and healthy uptake of IBM’s blockchain, security and other digital transformation offerings bode well in the long haul.

Nonetheless, intense competition in the cloud computing market from the likes of Amazon Web Services and Microsoft Azure is a major headwind. Higher debt levels amid extensive restructuring activities are other concerns.

(You can read the full research report on IBM here >>>)

Shares of Deere have gained +33.2% in the year-to-date period against the Zacks Manufacturing - Farm Equipment industry’s gain of +29.7%. Deere expects net income for fiscal 2021 between $4.6 billion and $5 billion backed by improving conditions in the farm and construction sectors. The mid-point of the range suggests year-over-year improvement of 75%. Pick-up in commodity prices bodes well for agricultural equipment demand. Further, replacement demand triggered by the need to replace old equipment will continue to boost the company's revenues.

The Zacks analyst believes that Deere’s focus on investing in new products with advanced technologies provides it a competitive edge. Additionally, the company's concerted efforts to expand in precision agriculture will drive growth in the long haul.

(You can read the full research report on Deere here >>>)

Other noteworthy reports we are featuring today include BHP Group (BHP), VALE S.A. (VALE) and Manulife Financial Corporation (MFC).

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Sheraz Mian

Director of Research

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Novo Nordisk's (NVO) Diabetes Drugs Aid Growth Amid Rivalry

Robust Uptake of Cloud Solutions Aids IBM Amid High Debt

Deere (DE) to Grow on Innovation & Improving End Markets

Featured Reports

High Margin Assets & Cost Management Aid Devon Energy (DVN)

Per the Zacks analyst Devon's strong production from high margins assets in five oil rich U.S. basins and efficient cost management will drive its performance over the long run.

Helmerich & Payne (HP) to Gain from Good Liquidity Position

The Zacks analyst likes Helmerich & Payne's low debt levels, both on an absolute and relative basis, and a lack of significant near-term maturities but is worried over the lower drilling activity.

Green Dot (GDOT) Rides on BaaS Platform Amid Rising Expenses

The Zacks Analyst likes Green Dot's strategy to expand its addressable market using banking-as-a-service (BaaS) account programs.

Manulife Financial (MFC) to Grow on Solid Asia Business

Per the Zacks analyst, Manulife is set to grow on solid Asia and Wealth and Asset Management business and a strong capital position.

Technology & Equipment Arm Aids DENTSPLY (XRAY), Forex Ails

Per the Zacks analyst, DENTSPLY has been gaining from the strength in its core Technology & Equipment unit.

High Iron Prices, Liquidity Aid BHP Group (BHP), Costs Ail

The Zacks analyst believes higher iron prices and BHP's strong cash flow, focus on lowering debt, and efforts to make operations more efficient will drive growth despite higher costs.

Adtalem (ATGE) Rides on Chamberlain's Growth Amid Pandemic

Per the Zacks analyst, Adtalem benefits from enrollment growth at Chamberlain University. However, COVID-19 related disruptions and increased variable costs may hurt margins.

New Upgrades

High Iron Prices, Cost Control Efforts to Drive Vale (VALE)

Per the Zacks analyst, high iron ore prices, efforts to lower debt levels and focus on improving quality, productivity and lowering costs will drive growth for Vale.

Global Expansion Efforts Aid SVB Financial (SIVB) Top Line

Per the Zacks analyst, supported by a solid balance sheet position, SVB Financial continues to take efforts to expand globally. These initiatives are expected to keep supporting revenue growth.

Solid Online Show Aids Abercrombie & Fitch's (ANF) Top Line

Per the Zacks analyst, Abercrombie & Fitch is gaining from expanded omni-channel capabilities along with solid traffic across its websites and apps. This led to digital net sales growth of 34% in Q4.

New Downgrades

Regulatory Concerns & Rising Competition Hurt Alibaba (BABA)

Per the Zacks analyst, regulatory concerns regarding Alibaba's monopolistic behavior alongwith intensifying competition in e-commerce as well as cloud computing market are overhangs.

Higher Spending Amid Stiff Competition Hurts Take Two (TTWO)

Per the Zacks analyst, intense competition from the likes of EA and Activision is compelling Take Two to spend more on game development and advertising thereby keeping margins under pressure.

InterDigital (IDCC) Hurt by Escalating Costs, Competition

Per the Zacks analyst, apart from stiff competition, InterDigital is struggling with escalating research and development costs to come up with innovative technology solutions in the wireless market.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
VALE S.A. (VALE) : Free Stock Analysis Report
Novo Nordisk AS (NVO) : Free Stock Analysis Report
Manulife Financial Corp (MFC) : Free Stock Analysis Report
International Business Machines Corporation (IBM) : Free Stock Analysis Report
Deere & Company (DE) : Free Stock Analysis Report
BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research